InotivNOTV
NOTV
About: Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Employees: 2,075
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
509% more capital invested
Capital invested by funds: $5.97M [Q3] → $36.4M (+$30.4M) [Q4]
460% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 5
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
182% more call options, than puts
Call options by funds: $2.43M | Put options by funds: $859K
49% more funds holding
Funds holding: 47 [Q3] → 70 (+23) [Q4]
14.03% more ownership
Funds ownership: 13.51% [Q3] → 27.54% (+14.03%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$5
149%
upside
Avg. target
$5
149%
upside
High target
$5
149%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Frank Takkinen 27% 1-year accuracy 6 / 22 met price target | 149%upside $5 | Buy Maintained | 8 May 2025 |
Financial journalist opinion
Based on 5 articles about NOTV published over the past 30 days
Neutral
Seeking Alpha
6 days ago
Inotiv, Inc. (NOTV) Q2 2025 Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:20 PM ET Inotiv, Inc. (NASDAQ:NOTV ) Q2 2025 Earnings Conference Call May 7, 2025, 04:30 PM ET Company Participants Steve Halper - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer John Sagartz - Chief Strategy Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Nelson Cox - Lake Street Capital Markets Dave Windley - Jefferies Operator Good day, everyone, and welcome to today's Inotiv Second Quarter Fiscal 2025 Earnings Call. [Operator Instructions] Please note, today's call will be recorded and I will be standing by should you need any assistance.
Negative
Zacks Investment Research
6 days ago
Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates
Inotiv, Inc. (NOTV) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.29 per share a year ago.
Neutral
GlobeNewsWire
6 days ago
Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update
— Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million— Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million— Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q2 FY 2025”) ended March 31, 2025 and six months ("YTD FY 2025") ended March 31, 2025.
Negative
Zacks Investment Research
2 weeks ago
Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Inotiv (NOTV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
2 weeks ago
Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025
WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, on Wednesday, May 7, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
Neutral
Seeking Alpha
3 months ago
Inotiv, Inc. (NOTV) Q1 2025 Earnings Call Transcript
Inotiv, Inc. (NASDAQ:NOTV ) Q1 2025 Results Conference Call February 5, 2025 4:30 PM ET Company Participants Steve Halper - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Dave Windley - Jefferies Operator Good day, everyone, and welcome to today's Inotiv First Quarter Fiscal 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Neutral
GlobeNewsWire
3 months ago
Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025
WEST LAFAYETTE, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, on Wednesday, February 5, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
Neutral
GlobeNewsWire
4 months ago
Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million
WEST LAFAYETTE, Ind., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised an additional $3.6 million in net proceeds from the optional shares in connection with its previously announced underwritten public offering of common shares. The Company issued the additional 900,000 shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the 900,000 optional shares of common stock on December 30, 2024.
Neutral
GlobeNewsWire
4 months ago
Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million
WEST LAFAYETTE, Ind., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised approximately $24.0 million in net proceeds from its underwritten public offering of 6,000,000 common shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the initial 6,000,000 common shares on December 19, 2024.
Neutral
GlobeNewsWire
4 months ago
Inotiv, Inc. Launches Proposed Public Offering of Common Shares
WEST LAFAYETTE, Ind., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced commencement of a proposed underwritten public offering of its common shares. All the shares will be offered by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional common shares in an amount of up to 15% of the number of shares sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Charts implemented using Lightweight Charts™